Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Aduro’s pancreatic cancer drug fails in mid-stage study

Aduro Biotech Inc said its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, in a mid-stage study.

Read More »

Biogen Aligns with Two Super Stars and Bags a Deal with REGENXBIO in Gene Therapy Push

Biogen has made several bold steps to further its work in gene therapy. The company announced a collaboration with two gene therapy experts from the University of Pennsylvania, as well as a gene therapy technology licensing deal with Maryland-based RegenxBio.

Read More »

Pfizer Slams Down $5.2 Billion for Bay Area Drugmaker Anacor

Pfizer is acquiring Palo Alto, California-based Anacor Pharmaceuticals for $5.2 billion.

Read More »

After Heart Drug Flunks Phase II Study, Trevena Makes Strategic Pivot to Focus on Pain Drugs

King of Prussia, Pennsylvania-based Trevena plans to shift its focus after its TRV027 flopped in a Phase IIb clinical trial for acute heart failure.

Read More »

Pfizer blocks its drugs from use in lethal injections

Pfizer Inc. has taken steps to ensure that none of its products are used in lethal injections, the largest U.S. drugmaker said.

Read More »

The HBA Honors Its 2016 Woman Of The Year: Jennifer Cook Of Roche

Roche’s Jennifer Cook is the Healthcare Businesswomen’s Association’s 2016 WOTY.

Read More »

Germany’s Merck says gene editing to help it outperform

Merck KGaA expects to continue delivering market-beating sales growth, helped in part by new gene modification techniques.

Read More »

Beyond immuno-oncology, AstraZeneca builds up ‘DNA damage’ drugs

Drugs targeting DNA repair mechanisms inside cells are showing real promise for a range of tumors.

Read More »

Mylan Acquiring Renaissance’s Topicals-Focused Business

Mylan N.V. announced an agreement to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings LLC for $950 million in cash at closing.

Read More »

Gutsy Sanofi to Nominate 8 Directors for Medivation Board, Files Pre-Merger Papers

Sanofi is not one to take no for an answer. Deal hungry Sanofi is carrying out its threats for a hostile takeover of Bay Area’s Medivation. Despite repeated rejections by that company’s board of directors on a possible merger, Sanofi said it plans to nominate eight directors to replace Medivation’s current board and has also filed pre-merger notifications with the Federal Trade Commission.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom